Targeted therapy for non-small-cell lung cancer: Past, present and future

Research output: Contribution to journalReview articlepeer-review


Therapy for advanced non-small-cell lung cancer has developed significantly with new awareness of histologic subtype as an important factor in guiding treatment and the development of targeted agents for molecular subgroups harboring critical mutations that spur on cancer growth. In this comprehensive review, we look back at developments in targeted therapy for advanced non-small-cell lung cancer, reviewing in detail efforts, both successful and in some cases less so, to target EGFR, VEGF and ALK. This review provides an overview of where the field stands at present and the areas we feel are most likely to provide challenges and potential successes in the next 5 years including immune checkpoint inhibition, epigenetic therapy and driver mutation targeting.

Original languageEnglish (US)
Pages (from-to)745-758
Number of pages14
JournalExpert Review of Anticancer Therapy
Issue number6
StatePublished - Jun 2013


  • PD1
  • VEGF
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Targeted therapy for non-small-cell lung cancer: Past, present and future'. Together they form a unique fingerprint.

Cite this